Synthetic Mucus Nanobarriers for Identification of Glycan-Dependent Primary Influenza A Infection Inhibitors
Year: 2016
Type: article
Abstract: Current drugs against the influenza A virus (IAV) act by inhibiting viral neuraminidase (NA) enzymes responsible for the release of budding virions from sialoglycans on infected cells. Here, we describe an approach focused on a search for inhibitors that reinforce the protective functions of mucosal barriers that trap viruses en route to the target cells. We have generated mimetics of sialo-glycoproteins that insert into the viral envelope to provide a well-defined mucus-like environment encapsulating the virus. By introducing this barrier, which the virus must breach using its NA enzymes to infect a host cell, into a screening platform, we have been able to identify compounds that provide significant protection against IAV infection. This approach may facilitate the discovery of potent new IAV prophylactics among compounds with NA activities too weak to emerge from traditional drug screens.
Source: ACS Central Science
Institution: University of California San Diego
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Funders: G. Harold and Leila Y. Mathers Charitable Foundation, National Institutes of Health, NIH Office of the Director, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G2041273731, NeoProteoglycans as synthetic materials for regenerative medicine and bioimaging, In vivo glycan engineering at the cell-matrix interface to control stem cell fate, University of California San Diego Neuroscience Microscopy Imaging Core, G7473867444, MOLECULAR BIOPHYSICS TRAINING PROGRAM
OpenAlex ID: W2524512366